Sign inJoin waitlistJoin the waitlist

Christine Pratilas

Vice Chair for Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center · Johns Hopkins University School of Medicine

Credentials: · · · ·

History

Sidney Kimmel Comprehensive Cancer Center · Johns Hopkins University School of Medicine
Present
Johns Hopkins University School of Medicine
Present

Pediatric Hematology-Oncology
2002–2003
Pediatrics
1999–2002
Doctor of Medicine
1995–1999

Research

BRAF mutation predicts sensitivity to MEK inhibition
Nature · 2006 · 1,094 citations
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
Proceedings of the National Academy of Sciences of the United States of America · 2009 · First of 7 authors · 540 citations
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
Cancer Cell · 2012 · 485 citations

David Solit
16 papers
NR
Neal Rosen
16 papers
Christian Meyer
15 papers
AH
Angela Hirbe
14 papers
Lindy Zhang
14 papers
Jaishri Blakeley
13 papers
AL
Adam Levin
12 papers
John Gross
12 papers
NL
Nicolas Llosa
11 papers
Allan Belzberg
10 papers
Daniel Rhee
10 papers
Fausto Rodriguez
10 papers

Grants

Advancing RAS Pathway Targeted Therapy in NF1-MPNST: Effects of SHP2 and CDK4/6 Inhibitors on the Tumor and the Tumor Immune Microenvironment
National Cancer Institute · R01
Contact PI · $2.3M · Johns Hopkins University
2023–2028
Feedback Regulation and Functional Output of the RAS/RAF/MEK/MAPK Pathway in Huma
National Cancer Institute · K08
Contact PI · $865.8K · Johns Hopkins University
2009–2014

Clinical trials

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2020–2027
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Site PI · Recruiting · Phase 3
Children's Oncology Group
2022–2030
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Site PI · Recruiting · Phase 1, Phase 2
Children's Oncology Group
2022–2026